KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Comparing the Efficacy and Safety of Fexuprazan and Lansoprazole for the Prevention of Nonsteroidal Anti-inflammatory Drug-Induced Peptic Ulcer.

Seokchan Hong, Ji Hyeon Ju, Sang-Heon Lee, Seung-Jae Hong, Sang-Hyon Kim, Ga Young Ahn, Jae Hyun Jung, Jin-Wuk Hur, You-Jung Ha, Jin Kyun Park, Hyun-Sook Kim, Sung Won Lee, Yong-Beom Park, Mie Jin Lim, Yun Sung Kim, Jung Soo Song, Chan-Bum Choi, Seong-Ho Kim, In Ah Choi, Kee Don Choi, Tae Hee Lee, Young Sin Cho, Yong Chan Lee, Kye Sook Kwon, Hyejung Lee, Mihee Park, Junga Heo, Song Baek, Chang-Keun Lee

Gut Liver 19(5) 685-695

PMID40567214
PMCIDPMC12436061
DOI10.5009/gnl250019
发表日期2025-06-26
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:AI 判定为 forest plot;Fig. 3:AI 判定为 other。
摘要

摘要

BACKGROUND/AIMS: To compare the efficacy and safety of fexuprazan and lansoprazole for preventing peptic ulcers (PUs) induced by nonsteroidal anti-inflammatory drugs (NSAIDs). METHODS: This multicenter, double-blind, randomized, active-controlled study was conducted across 32 hospitals in South Korea. Patients with musculoskeletal disease requiring long-term treatment with celecoxib, naproxen, or meloxicam were randomized to receive either fexuprazan 20 mg/day (n=212) or lansoprazole 15 mg/day (n=211) for 24 weeks. The primary endpoint was the occurrence of PUs, which were confirmed via esophagogastroduodenoscopy (EGD), with a non-inferiority margin of 8.3%. Only ulcers that developed during the treatment period were examined in the analysis. The occurrence of gastroduodenal bleeding was also monitored via EGD, and symptoms were assessed by using the Patient Assessment of Upper Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM). Adverse events were recorded during the study. RESULTS: The incidence rate of EGD-confirmed PUs at week 24 was 1.16% in the fexuprazan group and 2.76% in the lansoprazole group, with a between-group difference of -1.64% (95% confidence interval, -4.52% to 1.25%), demonstrating non-inferiority. No patients presented with gastroduodenal bleeding. No significant between-group differences were found in the PAGI-SYM scores (leastsquare mean difference in the total score at week 24, -0.42; 95% confidence interval, -2.48 to 1.64; p=0.69). There were low rates of adverse drug reactions in the fexuprazan and lansoprazole groups (8.57% vs 4.78%, respectively p=0.12). CONCLUSIONS: Given its non-inferiority to lansoprazole and similar safety profile, fexuprazan is a promising alternative for the prevention of NSAID-induced PUs (ClinicalTrials.gov identifier NCT04784910).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Distribution of patients. NSAID, nonsteroidal anti-inflammatory drug.
非 KM Figure
Fig. 2Fig. 2 Common risk difference in the incidence of esophagogastroduodenoscopy-confirmed peptic ulcer for 24 weeks of treatment. The main analysis and sensitivity analysis were carried out using a full-analysis set. PPS, per-protocol set; CI, confidence interval.
非 KM Figure
Fig. 3Fig. 3 Patient-reported symptoms based on the Patient Assessment of Upper Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM). (A) Least-square (LS) mean changes in symptom scores. (B) Proportion of patients with resolution or development of symptoms based on changes in symptom scores. The bars on the right side of each graph represent the proportions of patients whose PAGI-SYM symptom score increased by at least 1 from 0 at baseline, whereas the bars on the left side represent the proportions of patients whose PAGI-SYM symptom score changed to 0 from positive numbers at baseline. EOT, end-of-treatment.
非 KM Figure